Compare Stocks: VYNE, LONA, TLPH, and SPRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.55 -1.7%	$8.33	$3.52 ▼ $14.21	$70.89M	2.05	50,765 shs	7,691 shs
SPRO Spero Therapeutics	$1.24 -2.0%	$2.00	$1.08 ▼ $3.08	$71.51M	1.55	877,377 shs	217,455 shs
TLPH Talphera	$1.42 -1.0%	$1.14	$0.40 ▼ $1.57	$73.44M	0.69	244,291 shs	80,418 shs
VYNE VYNE Therapeutics	$28.33 -0.8%	$33.04	$14.03 ▼ $79.75	$18.98M	2	44,151 shs	93,278 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	0.00%	+8.78%	-20.00%	-23.28%	+767,999,900.00%
SPRO Spero Therapeutics	0.00%	+7.69%	-40.00%	-50.59%	-42.47%
TLPH Talphera	0.00%	+11.72%	-2.05%	+64.84%	+249.21%
VYNE VYNE Therapeutics	0.00%	0.00%	-11.15%	-14.75%	+58.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.55 -1.7%	$8.33	$3.52 ▼ $14.21	$70.89M	2.05	50,765 shs	7,691 shs
SPRO Spero Therapeutics	$1.24 -2.0%	$2.00	$1.08 ▼ $3.08	$71.51M	1.55	877,377 shs	217,455 shs
TLPH Talphera	$1.42 -1.0%	$1.14	$0.40 ▼ $1.57	$73.44M	0.69	244,291 shs	80,418 shs
VYNE VYNE Therapeutics	$28.33 -0.8%	$33.04	$14.03 ▼ $79.75	$18.98M	2	44,151 shs	93,278 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	0.00%	+8.78%	-20.00%	-23.28%	+767,999,900.00%
SPRO Spero Therapeutics	0.00%	+7.69%	-40.00%	-50.59%	-42.47%
TLPH Talphera	0.00%	+11.72%	-2.05%	+64.84%	+249.21%
VYNE VYNE Therapeutics	0.00%	0.00%	-11.15%	-14.75%	+58.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LONA Athira Pharma	2.50	Moderate Buy	$16.00	111.92% Upside
SPRO Spero Therapeutics	1.50	Reduce	N/A	N/A
TLPH Talphera	2.25	Hold	$3.00	112.01% Upside
VYNE VYNE Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest VYNE, LONA, TLPH, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	TLPH Talphera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/5/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.00
5/27/2026	LONA Athira Pharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
5/11/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SPRO Spero Therapeutics	$66.80M	1.07	$0.15 per share	8.28	$1.05 per share	1.18
TLPH Talphera	$1K	73,438.50	N/A	N/A	$0.37 per share	3.82
VYNE VYNE Therapeutics	$570K	33.29	N/A	N/A	$41.71 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LONA Athira Pharma	-$105.61M	-$5.21	N/A	N/A	N/A	N/A	-381.01%	-225.74%	N/A
SPRO Spero Therapeutics	$8.57M	$0.24	5.15	N/A	N/A	24.90%	35.58%	24.95%	8/12/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.31	N/A	N/A	N/A	N/A	-92.98%	-53.22%	8/13/2026 (Estimated)
VYNE VYNE Therapeutics	-$26.48M	-$0.38	N/A	N/A	N/A	-4,726.21%	-70.42%	-63.46%	8/13/2026 (Estimated)

Latest VYNE, LONA, TLPH, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TLPH Talphera	-$0.07	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	VYNE VYNE Therapeutics	-$0.18	N/A	N/A	N/A	$0.20 million	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	N/A	N/A	N/A	$0.28 million	N/A
5/15/2026	Q1 2026	VYNE VYNE Therapeutics	-$9.00	-$4.00	+$5.00	-$0.08	$0.20 million	$0.09 million
5/13/2026	Q1 2026	SPRO Spero Therapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$0.26 million	$0.26 million
5/13/2026	Q1 2026	TLPH Talphera	-$0.07	-$0.04	+$0.03	-$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VYNE, LONA, TLPH, and SPRO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	VYNE VYNE Therapeutics	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LONA Athira Pharma	N/A	10.38	10.38
SPRO Spero Therapeutics	N/A	10.50	10.50
TLPH Talphera	N/A	5.30	5.30
VYNE VYNE Therapeutics	N/A	20.86	20.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LONA Athira Pharma	57.12%
SPRO Spero Therapeutics	25.60%
TLPH Talphera	37.67%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
LONA Athira Pharma	25.73%
SPRO Spero Therapeutics	2.90%
TLPH Talphera	3.50%
VYNE VYNE Therapeutics	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
SPRO Spero Therapeutics	150	57.90 million	56.22 million	Optionable
TLPH Talphera	19	51.90 million	50.08 million	Optionable
VYNE VYNE Therapeutics	30	670,000	648,000	Not Optionable

VYNE, LONA, TLPH, and SPRO Headlines

Recent News About These Companies

VYNE Therapeutics (VYNE) Projected to Post Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Guardian Pharmacy Services (NYSE:GRDN) versus VYNE Therapeutics (NASDAQ:VYNE) Critical Contrast

August 3, 2026 | americanbankingnews.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase - Here's Why

July 27, 2026 | marketbeat.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...

July 22, 2026 | finanznachrichten.de

VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update

July 22, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 21, 2026 | globenewswire.com

Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend?

July 10, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience

July 10, 2026 | quiverquant.comQ

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 10, 2026 | globenewswire.com

VYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | Benzinga

July 1, 2026 | benzinga.com

VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04

May 15, 2026 | msn.com

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

December 18, 2025 | prnewswire.com

3 penny stocks to watch now, 12/18/25

December 18, 2025 | msn.com

VYNE to merge with Yarrow in $200 million deal

December 18, 2025 | thepharmaletter.comT

Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience

December 17, 2025 | pharmexec.comP

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

December 17, 2025 | prnewswire.com

VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

December 17, 2025 | businesswire.com

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

December 17, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE, LONA, TLPH, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

$7.55 -0.13 (-1.69%)

As of 02:57 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Spero Therapeutics NASDAQ:SPRO

$1.24 -0.03 (-1.98%)

As of 03:00 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Talphera NASDAQ:TLPH

$1.42 -0.02 (-1.05%)

As of 02:59 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

VYNE Therapeutics NASDAQ:VYNE

$28.32 -0.24 (-0.82%)

Closing price 07/27/2026

Extended Trading

$28.32 0.00 (0.00%)

As of 07/27/2026 07:48 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYNE, LONA, TLPH, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYNE, LONA, TLPH, and SPRO Earnings

Compare Dividends

Latest VYNE, LONA, TLPH, and SPRO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYNE, LONA, TLPH, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE, LONA, TLPH, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

VYNE Therapeutics NASDAQ:VYNE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYNE, LONA, TLPH, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYNE, LONA, TLPH, and SPRO Earnings

Compare Dividends

Latest VYNE, LONA, TLPH, and SPRO Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYNE, LONA, TLPH, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE, LONA, TLPH, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

VYNE Therapeutics NASDAQ:VYNE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools